Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Finished Goods (2016 - 2020)

United Therapeutics (UTHR) has disclosed Finished Goods for 11 consecutive years, with $43.8 million as the latest value for Q1 2020.

  • Quarterly Finished Goods fell 7.98% to $43.8 million in Q1 2020 from the year-ago period, while the trailing twelve-month figure was $43.8 million through Mar 2020, down 7.98% year-over-year, with the annual reading at $43.2 million for FY2019, 11.29% down from the prior year.
  • Finished Goods hit $43.8 million in Q1 2020 for United Therapeutics, up from $43.2 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $62.2 million in Q3 2017 to a low of $37.3 million in Q2 2016.
  • Historically, Finished Goods has averaged $48.9 million across 5 years, with a median of $48.7 million in 2018.
  • Biggest five-year swings in Finished Goods: soared 65.15% in 2017 and later decreased 20.58% in 2018.
  • Year by year, Finished Goods stood at $49.7 million in 2016, then rose by 12.47% to $55.9 million in 2017, then fell by 12.88% to $48.7 million in 2018, then fell by 11.29% to $43.2 million in 2019, then increased by 1.39% to $43.8 million in 2020.
  • Business Quant data shows Finished Goods for UTHR at $43.8 million in Q1 2020, $43.2 million in Q4 2019, and $45.0 million in Q3 2019.